Pillai, Rathi N <br/><br/>
Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  02 2020 
 - 613-622 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.19.00816  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Docetaxel--therapeutic use<br/>Female<br/>HSP90 Heat-Shock Proteins--antagonists & inhibitors<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Progression-Free Survival<br/>Salvage Therapy--methods<br/>Treatment Outcome<br/>Triazoles--therapeutic use